Brock A
University of Aarhus, Department of Clinical Chemistry, Randers Centralsygehus, Denmark.
J Clin Chem Clin Biochem. 1990 Nov;28(11):851-6. doi: 10.1515/cclm.1990.28.11.851.
Substance concentrations of plasma cholinesterase (EC 3.1.1.8) were measured in 94 healthy individuals without occupational exposure to known inhibitors (six samples from each individual). Immunoreactive cholinesterase substance concentrations showed an inter-individual variation corresponding to CVtotal = 22% (mean: 5.01 mg/l, SD: 1.11 mg/l). Intra-individual variations of immunoreactive cholinesterase substance concentration were correlated (r = 0.36) to intra-individual variation of albumin. Estimated by a repeated-measures analysis of variance, the observed intra-individual variation of cholinesterase substance concentration corresponded to CV = 8.8% (SD: 0.44 mg/l), which together with a CVerror = 6% (within and between runs), implies a biological intra-individual variation of cholinesterase substance concentration corresponding to CVintra = 6.4%. Specific catalytic activity (kU/mg immunoreactive cholinesterase) was influenced by the ChE-1 phenotype (phenotype U: 1.58 kU/mg, phenotype UA: 1.22 kU/mg), but not by body weight, height, age, and sex. Observed intra-individual variation of specific catalytic activity corresponded to 6.4% (SD: 0.10 kU/mg), which together with an estimated CVerror = 6.2% implies the biological intra-individual variations of specific catalytic cholinesterase activity to be insignificant. The insignificant CVintra makes specific catalytic cholinesterase activity a rational quantity for evaluation of unexpected fluctuations of cholinesterase activity concentrations.
在94名无职业性接触已知抑制剂的健康个体中(每人采集6份样本)测量了血浆胆碱酯酶(EC 3.1.1.8)的物质浓度。免疫反应性胆碱酯酶物质浓度显示个体间变异对应于CVtotal = 22%(均值:5.01 mg/l,标准差:1.11 mg/l)。免疫反应性胆碱酯酶物质浓度的个体内变异与白蛋白的个体内变异相关(r = 0.36)。通过重复测量方差分析估计,观察到的胆碱酯酶物质浓度个体内变异对应于CV = 8.8%(标准差:0.44 mg/l),这与CVerror = 6%(批内和批间)一起,意味着胆碱酯酶物质浓度的生物学个体内变异对应于CVintra = 6.4%。比催化活性(kU/mg免疫反应性胆碱酯酶)受ChE - 1表型影响(表型U:1.58 kU/mg,表型UA:1.22 kU/mg),但不受体重、身高、年龄和性别的影响。观察到的比催化活性个体内变异对应于6.4%(标准差:0.10 kU/mg),这与估计的CVerror = 6.2%一起意味着比催化胆碱酯酶活性的生物学个体内变异不显著。CVintra不显著使得比催化胆碱酯酶活性成为评估胆碱酯酶活性浓度意外波动的合理指标。